CLOV

Clover Health Investments, Corp. Class A Common Stock (CLOV) | Rumor.io

Clover Health Investments

CLOV

Attention (50-day avg)0.03%

Attention rank (50-day avg)#221

Bullish sentiment (50-day avg)68%

Price to earnings ratio-25.5

Market capitalization2.3B

Earnings per share-0.05

Dividend yield (TTM)—

Revenue (annual)1.9B

Net income (annual)-85.5M

Social

What share of all stock conversation is about CLOV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% -0.26	0.06% +0.04	0.03% -0.02	0.03% -0.13

Sep 30

Clover Health Investments, Corp. may make a significant growth push in South Carolina this year.
The company is increasing its benefits to approach those offered by Humana and United.
Clover's stock price may be due for a long-term increase in value, but patience is required.

Generated by AI

Sentiment

Of the messages about CLOV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% +27.27	59.1% -8.58	68.27% +1.12	68.39% -9.3
Bearish	33.33% -27.27	40.9% +8.58	31.73% -1.12	31.61% +9.3

Bullish· Sep 17

Clover Health's strong fundamentals, including 55.6% revenue growth and $28M in net income, are gaining traction and may lead to sustained stock momentum.
The company's expansion, with no debt and recent analyst upgrades, positions it for a potential breakout above $4.61, triggering macro continuation towards $5.16 and $7.11.
Clover Health's strong growth prospects, including 48% YOY AEP membership growth and 98% AEP membership retention, make it a better investment in healthcare, with potential targets of $10-15 by Q1 2027.

Bearish· Sep 25

The SEC's alleged complicity with market makers and the existence of cases against them may be a factor in Clover Health's current state.
The company's high prior auth denial rates and alleged fraud, waste, and abuse may have contributed to a significant portion of its members being disenrolled.
The stock market's transparency and the SEC's effectiveness in protecting investors are questioned, suggesting a rigged market that may be working against Clover Health.

Generated by AI

Topics

Of the messages about CLOV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	84.02%	43.67%	7.43%
Analysts	—	1.78%	40.87%	38.22%
Earnings	—	0%	0.78%	14.33%
Technical Analysis	—	12.43%	8.73%	1.9%
Controversies	—	0%	2.46%	1.98%
Macro	—	1.78%	3.47%	36.14%

Earnings· Aug 6

Clover Health's Q2 earnings were strong, with revenue increasing 55.6% YoY to $743M and guidance raised across every metric, including revenue, EBITDA, and net income.
The company's growth and improving cost ratio combo is notable, with a 48.7% membership growth rate and a 2% BER improvement to 87.6% YoY.
Despite beating earnings expectations, Clover Health's stock price action was weak, with a 25% decline on no news, and the company's working profitability model and raised guidance may not be enough to boost investor confidence.

Analysts· Sep 10

Deutsche Bank initiated coverage on Clover Health Investments with a Buy rating and a price target of $6.00, viewing the company as an investment in the expanding Medicare Advantage market at an attractive valuation.
The analyst firm identifies Clover's emerging technology-enabled Medicare Advantage provider status, key differentiators, including the Clover Assistant, software platform, and non-delegated risk model, as drivers of the company's earnings.
Clover's valuation is seen as attractive, with the firm citing the company's position in the Medicare Advantage market as a key factor in their investment decision.

Announcements· Apr 9

Clover Health's Broker Assistant has been nominated for a Webby Award in AI – Customer Experience or CRM, and public voting is open through April 16.
A demo is using Clover Health's HealthEx and showing Counterpart, but this does not necessarily prove a partnership between the two companies.
Clover Health's Broker Assistant was built to make Medicare Advantage less confusing for brokers, and the company is proud to see its work getting recognized by the Webby Awards.

Controversies· May 28

Clover Health Investments, Corp. (CLOV) may have selectively appealed measures to CMS that had low scores, raising questions about the fairness of the process.
The company's appeal process may have created an uneven playing field, where certain measures are excluded based on their scores.
CMS's handling of CLOV's appeals has sparked controversy, with some questioning whether other measures with higher scores should also be excluded.

Macro· May 11

Clover Health's profitability in 2025 is expected, with Wall Street only just catching on.
Tariff policies similar to Trump's have been tried before, leading to recession or depression.
A recession is likely, possibly already started, which could make CLOV a good investment opportunity.

Technical Analysis· Oct 21

$CLOV has broken the 200SMA at $3.33 with volume, indicating a potential continuation of the rally.
A break of the trendline near $3.35 is expected to lead to a quick rally to the 200 DMA, with some analysts predicting a move to the $4 area.
The stock is near resistance, and a pullback to the low $3s is being watched to determine if the current move is sustainable.

Generated by AI

Community

Of the messages about CLOV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	99.52%	97.84%	94.28%	91.95%
Newcomers	0.48%	2.16%	5.72%	8.05%

Regulars· Sep 30

Clover Health is expected to make a significant growth push in South Carolina this year, potentially leading to increased business opportunities and expansion.
The company's growth strategy is expected to bring it closer to the offerings of Humana and United, which may improve its competitive position in the market.
Clover Health's ability to provide comprehensive benefits, including prescription drugs, is a key factor in its growth and competitiveness, and recent changes to its benefit plans may have a positive impact on its business.

Newcomers· Sep 15

Many newcomers are focusing on the potential impact of a 4-star rating or higher for 2028 on Clover Health's stock price, with some expecting it to trade above $9-10.
Some traders are anticipating news about the Humana partnership to be revealed at an upcoming conference, which could be a significant catalyst for the stock.
Newcomers are also speculating about a potential "pop" in the stock price, with some expecting it to climb to $5.50 or higher, and others wondering how long the current drop will last.

Generated by AI

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

4d agoYahoo Finance

Clover Health adds two directors to board of directors

5d agoInvesting.com

UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors

5d agoYahoo Finance

Clover Health adds two directors to board

5d agoInvesting.com

Clover Corp Ltd (ASX:CLV) (FY 2026) Earnings Call Highlights: Record Revenue, 50% Profit Surge, ...

7d agoYahoo Finance

Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens

Clover Health Investments (NASDAQ:CLOV) is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies’ Healthcare Services and Technology Conference in

11d agoYahoo Finance

Also Discussed

Investors talking about CLOV also mention

#	Name	Attention
1	Workhorse Group Inc.WKHS	0%0
2	Vinco Ventures Inc.BBIG	0%+0
3	Alignment Healthcare, Inc.ALHC	0%0
4	Humana Inc.HUM	0%+0
5	Clean Energy Fuels Corp.CLNE	0%0
6	UWM Holdings CorporationUWMC	0%0
7	AMC Entertainment Holdings, Inc. Class A Common StockAMC	0.83%-0.19
8	CARV - Carver Bancorp, Inc.	——
9	FuboTV Inc. Class A Common StockFUBO	0%+0
10	Aterian Inc.ATER	0%new

Clover Health Investments, Corp. Class A Common Stock

Healthcare
Healthcare Plans

Clover Health Investments, Corp. Class A Common Stock represents an equity interest in Clover Health Investments, Corp., a healthcare company focused on Medicare Advantage plans in the United States. The company serves Medicare-eligible individuals through preferred provider organization and health maintenance organization plans, with a strong emphasis on broad-network coverage and coordinated care. Clover Health also operates Clover Assistant, a proprietary software platform that supports physicians by aggregating patient data and helping identify and manage chronic conditions earlier. Its business is centered on the insurance segment, combining managed care offerings with technology-enabled clinical support for medical providers. Based in Wilmington, Delaware, Clover Health occupies a niche in the healthcare market where insurance delivery and data-driven care management intersect.

Website

Location

1209 Orange Street

Wilmington, DE, 19801

United States

Social

What share of all stock conversation is about CLOV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% -0.26	0.06% +0.04	0.03% -0.02	0.03% -0.13

Sep 30

Clover Health Investments, Corp. may make a significant growth push in South Carolina this year.
The company is increasing its benefits to approach those offered by Humana and United.
Clover's stock price may be due for a long-term increase in value, but patience is required.

Generated by AI

Sentiment

Of the messages about CLOV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% +27.27	59.1% -8.58	68.27% +1.12	68.39% -9.3
Bearish	33.33% -27.27	40.9% +8.58	31.73% -1.12	31.61% +9.3

Bullish· Sep 17

Clover Health's strong fundamentals, including 55.6% revenue growth and $28M in net income, are gaining traction and may lead to sustained stock momentum.
The company's expansion, with no debt and recent analyst upgrades, positions it for a potential breakout above $4.61, triggering macro continuation towards $5.16 and $7.11.
Clover Health's strong growth prospects, including 48% YOY AEP membership growth and 98% AEP membership retention, make it a better investment in healthcare, with potential targets of $10-15 by Q1 2027.

Bearish· Sep 25

The SEC's alleged complicity with market makers and the existence of cases against them may be a factor in Clover Health's current state.
The company's high prior auth denial rates and alleged fraud, waste, and abuse may have contributed to a significant portion of its members being disenrolled.
The stock market's transparency and the SEC's effectiveness in protecting investors are questioned, suggesting a rigged market that may be working against Clover Health.

Generated by AI

Topics

Of the messages about CLOV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	84.02%	43.67%	7.43%
Analysts	—	1.78%	40.87%	38.22%
Earnings	—	0%	0.78%	14.33%
Technical Analysis	—	12.43%	8.73%	1.9%
Controversies	—	0%	2.46%	1.98%
Macro	—	1.78%	3.47%	36.14%

Earnings· Aug 6

Clover Health's Q2 earnings were strong, with revenue increasing 55.6% YoY to $743M and guidance raised across every metric, including revenue, EBITDA, and net income.
The company's growth and improving cost ratio combo is notable, with a 48.7% membership growth rate and a 2% BER improvement to 87.6% YoY.
Despite beating earnings expectations, Clover Health's stock price action was weak, with a 25% decline on no news, and the company's working profitability model and raised guidance may not be enough to boost investor confidence.

Analysts· Sep 10

Deutsche Bank initiated coverage on Clover Health Investments with a Buy rating and a price target of $6.00, viewing the company as an investment in the expanding Medicare Advantage market at an attractive valuation.
The analyst firm identifies Clover's emerging technology-enabled Medicare Advantage provider status, key differentiators, including the Clover Assistant, software platform, and non-delegated risk model, as drivers of the company's earnings.
Clover's valuation is seen as attractive, with the firm citing the company's position in the Medicare Advantage market as a key factor in their investment decision.

Announcements· Apr 9

Clover Health's Broker Assistant has been nominated for a Webby Award in AI – Customer Experience or CRM, and public voting is open through April 16.
A demo is using Clover Health's HealthEx and showing Counterpart, but this does not necessarily prove a partnership between the two companies.
Clover Health's Broker Assistant was built to make Medicare Advantage less confusing for brokers, and the company is proud to see its work getting recognized by the Webby Awards.

Controversies· May 28

Clover Health Investments, Corp. (CLOV) may have selectively appealed measures to CMS that had low scores, raising questions about the fairness of the process.
The company's appeal process may have created an uneven playing field, where certain measures are excluded based on their scores.
CMS's handling of CLOV's appeals has sparked controversy, with some questioning whether other measures with higher scores should also be excluded.

Macro· May 11

Clover Health's profitability in 2025 is expected, with Wall Street only just catching on.
Tariff policies similar to Trump's have been tried before, leading to recession or depression.
A recession is likely, possibly already started, which could make CLOV a good investment opportunity.

Technical Analysis· Oct 21

$CLOV has broken the 200SMA at $3.33 with volume, indicating a potential continuation of the rally.
A break of the trendline near $3.35 is expected to lead to a quick rally to the 200 DMA, with some analysts predicting a move to the $4 area.
The stock is near resistance, and a pullback to the low $3s is being watched to determine if the current move is sustainable.

Generated by AI

Community

Of the messages about CLOV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	99.52%	97.84%	94.28%	91.95%
Newcomers	0.48%	2.16%	5.72%	8.05%

Regulars· Sep 30

Clover Health is expected to make a significant growth push in South Carolina this year, potentially leading to increased business opportunities and expansion.
The company's growth strategy is expected to bring it closer to the offerings of Humana and United, which may improve its competitive position in the market.
Clover Health's ability to provide comprehensive benefits, including prescription drugs, is a key factor in its growth and competitiveness, and recent changes to its benefit plans may have a positive impact on its business.

Newcomers· Sep 15

Many newcomers are focusing on the potential impact of a 4-star rating or higher for 2028 on Clover Health's stock price, with some expecting it to trade above $9-10.
Some traders are anticipating news about the Humana partnership to be revealed at an upcoming conference, which could be a significant catalyst for the stock.
Newcomers are also speculating about a potential "pop" in the stock price, with some expecting it to climb to $5.50 or higher, and others wondering how long the current drop will last.

Generated by AI

Clover Health Investments

Social

Sep 30

Bullish· Sep 17

Bearish· Sep 25

Earnings· Aug 6

Analysts· Sep 10

Announcements· Apr 9

Controversies· May 28

Macro· May 11

Technical Analysis· Oct 21

Regulars· Sep 30

Newcomers· Sep 15

1 Cash-Producing Stock on Our Buy List and 2 We Ignore

Clover Health adds two directors to board of directors

UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors

Clover Health adds two directors to board

Clover Corp Ltd (ASX:CLV) (FY 2026) Earnings Call Highlights: Record Revenue, 50% Profit Surge, ...

Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens

Also Discussed

Clover Health Investments, Corp. Class A Common Stock

Company Information

Location

1 Cash-Producing Stock on Our Buy List and 2 We Ignore

Clover Health adds two directors to board of directors

UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors

Clover Health adds two directors to board

Clover Corp Ltd (ASX:CLV) (FY 2026) Earnings Call Highlights: Record Revenue, 50% Profit Surge, ...

Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens

Also Discussed

Social

Sep 30

Bullish· Sep 17

Bearish· Sep 25

Earnings· Aug 6

Analysts· Sep 10

Announcements· Apr 9

Controversies· May 28

Macro· May 11

Technical Analysis· Oct 21

Regulars· Sep 30

Newcomers· Sep 15